Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 10/20 | 0.59 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.57 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.53 |
| ▸ | BID | P55957 | 2/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1702073 | 1.00 | BCL2 (0.59) | BCL2BCL2L1BCL2A1BIDMCL1 | |
| SCHEMBL2723710 | 0.97 | BCL2 (0.56) | BCL2BCL2L1BCL2A1BIDMCL1 | |
| SCHEMBL31450632 | 0.93 | BCL2 (0.61) | BCL2BCL2L1BCL2A1BIDMCL1 | |
| SCHEMBL26648191 | 0.93 | BCL2 (0.61) | BCL2BCL2L1BCL2A1BIDMCL1 | |
| SCHEMBL31450744 | 0.91 | BCL2A1 (0.63) | BCL2BCL2L1BCL2A1BIDMCL1 | |
| SCHEMBL1701594 | 0.91 | BCL2A1 (0.63) | BCL2BCL2L1BCL2A1BIDMCL1 | |
| SCHEMBL31450861 | 0.88 | BCL2 (0.54) | BCL2BCL2L1BCL2A1BIDMCL1 | |
| SCHEMBL26648210 | 0.88 | BCL2 (0.54) | BCL2BCL2L1BCL2A1BIDMCL1 | |
| SCHEMBL31450616 | 0.86 | BCL2A1 (0.58) | BCL2BCL2L1BCL2A1BIDMCL1 | |
| SCHEMBL26647890 | 0.86 | BCL2A1 (0.58) | BCL2BCL2L1BCL2A1BIDMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |